ZA200204380B - Partial or full A1 agonists-N6 heterocyclic 5'-thio substituted adenosine derivatives. - Google Patents

Partial or full A1 agonists-N6 heterocyclic 5'-thio substituted adenosine derivatives.

Info

Publication number
ZA200204380B
ZA200204380B ZA200204380A ZA200204380A ZA200204380B ZA 200204380 B ZA200204380 B ZA 200204380B ZA 200204380 A ZA200204380 A ZA 200204380A ZA 200204380 A ZA200204380 A ZA 200204380A ZA 200204380 B ZA200204380 B ZA 200204380B
Authority
ZA
South Africa
Prior art keywords
agonists
heterocyclic
partial
full
adenosine derivatives
Prior art date
Application number
ZA200204380A
Other languages
English (en)
Inventor
Jeff A Zablocki
Venkata P Palle
Vaibhav Verkhedkar
Luiz Belardinelli
Prabha N Ibrahim
Original Assignee
Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapeutics Inc filed Critical Therapeutics Inc
Publication of ZA200204380B publication Critical patent/ZA200204380B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA200204380A 1999-12-03 2002-05-31 Partial or full A1 agonists-N6 heterocyclic 5'-thio substituted adenosine derivatives. ZA200204380B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/454,136 US6605597B1 (en) 1999-12-03 1999-12-03 Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives

Publications (1)

Publication Number Publication Date
ZA200204380B true ZA200204380B (en) 2003-06-25

Family

ID=23803455

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200204380A ZA200204380B (en) 1999-12-03 2002-05-31 Partial or full A1 agonists-N6 heterocyclic 5'-thio substituted adenosine derivatives.

Country Status (25)

Country Link
US (2) US6605597B1 (es)
EP (1) EP1233973B1 (es)
JP (1) JP4021195B2 (es)
KR (1) KR100484988B1 (es)
CN (1) CN1152042C (es)
AR (1) AR029199A1 (es)
AT (1) ATE254133T1 (es)
AU (3) AU4138701A (es)
BR (1) BR0016126A (es)
CA (1) CA2389264C (es)
CZ (1) CZ20013705A3 (es)
DE (1) DE60006576T2 (es)
DK (1) DK1233973T3 (es)
ES (1) ES2208437T3 (es)
HK (1) HK1047941A1 (es)
HU (1) HUP0500455A2 (es)
IL (1) IL145903A (es)
MX (1) MXPA01011113A (es)
NO (1) NO20015373L (es)
NZ (1) NZ514777A (es)
PT (1) PT1233973E (es)
TR (2) TR200301971T4 (es)
TW (1) TWI249536B (es)
WO (2) WO2001040243A2 (es)
ZA (1) ZA200204380B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
CA2439222C (en) * 2000-02-23 2009-07-14 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
GB2372742A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
GB2372741A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,8-Disubstituted adenosine derivatives and their different uses
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
KR20040084929A (ko) * 2002-02-19 2004-10-06 씨브이 쎄러퓨틱스, 인코포레이티드 부분적이거나 완전한 ａ1 아데노신 수용체의 작용제
ATE418991T1 (de) * 2002-04-18 2009-01-15 Cv Therapeutics Inc Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
NZ537975A (en) * 2002-07-29 2007-08-31 Cv Therapeutics Inc Method of producing coronary vasodilation without peripheral vasodilation comprising administering at least 10 mcg of at least one A2A receptor agonist
CA2515068A1 (en) 2003-02-03 2004-08-19 Cv Therapeutics Inc. Partial and full agonists of a1 adenosine receptors
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
JP2007509180A (ja) 2003-10-21 2007-04-12 インスパイアー ファーマシューティカルズ，インコーポレイティド 疼痛を治療するための、非ヌクレオチド組成物および方法
EP1685135B1 (en) 2003-10-21 2010-05-26 Inspire Pharmaceuticals, Inc. TETRAHYDRO-FURO[3,4-d]DIOXOLE COMPOUNDS AND COMPOSITIONS AND METHOD FOR INHIBITING PLATELET AGGREGATION
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
ES2383525T3 (es) * 2003-11-05 2012-06-21 Sarcode Bioscience Inc. Moduladores de la adhesión celular
JP2008517063A (ja) 2004-10-20 2008-05-22 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ａアデノシンレセプターアゴニストの使用
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
PT1881823E (pt) 2005-05-17 2015-03-02 Sarcode Bioscience Inc Composições e métodos para o tratamento de transtornos oculares
CA2627319A1 (en) * 2005-11-30 2007-06-07 Prakash Jagtap Purine derivatives and methods of use thereof
CA2640089C (en) 2006-02-03 2013-07-23 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
WO2007107598A1 (en) 2006-03-21 2007-09-27 Heinrich-Heine-Universität Düsseldorf Phosphorylated a2a receptor agonists
CA2655310A1 (en) * 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
BRPI0716174A2 (pt) * 2006-09-01 2013-09-24 Cv Therapeutics Inc mÉtodos e composiÇÕes para aumentar a tolerabilidade de paciente durante mÉtodos de imagem do miocÁrdio.
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
CA2663361A1 (en) * 2006-09-29 2008-04-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
JP2010515081A (ja) * 2007-01-03 2010-05-06 ギリアード・パロ・アルト・インコーポレイテッド 心筋灌流画像化
MX2010004281A (es) 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
CN102014959B (zh) 2008-03-10 2016-01-20 康奈尔大学 血脑屏障通透性的调节
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
JP2011516607A (ja) * 2008-04-15 2011-05-26 サーコード コーポレイション 胃腸系へのｌｆａ−１アンタゴニストの送達
EP2265125B1 (en) * 2008-04-15 2019-08-14 SARcode Bioscience Inc. Topical lfa-1 antagonists for use in localized treatment of immune related disorders
US20090257957A1 (en) * 2008-04-15 2009-10-15 John Burnier Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders
AU2009296235A1 (en) * 2008-09-29 2010-04-01 Gilead Sciences, Inc. Combinations of a rate control agent and an A-2-alpha receptor antagonist for use in multidetector computed tomography methods
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
CN101934559B (zh) * 2010-08-12 2013-04-17 中国电子科技集团公司第四十五研究所 具有压力调节机构的砂浆供给装置
EP3715345B8 (en) 2012-07-25 2024-05-29 Bausch + Lomb Ireland Limited Preparation of lfa-1 inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4373097A (en) 1981-04-27 1983-02-08 Bioresearch S.R.L. Process for preparing adenosine derivatives of anti-inflammatory and analgesic activity
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
US5789419A (en) * 1994-06-09 1998-08-04 Ss Pharmaceutical Co., Ltd. 4-quinolinone derivative or salt thereof
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
GB9723566D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives

Also Published As

Publication number Publication date
EP1233973A1 (en) 2002-08-28
NO20015373L (no) 2001-11-29
CZ20013705A3 (cs) 2002-04-17
TR200103129T2 (tr) 2002-10-21
CN1378550A (zh) 2002-11-06
AU4138701A (en) 2001-06-12
AU1811701A (en) 2001-06-12
KR100484988B1 (ko) 2005-04-22
KR20030032907A (ko) 2003-04-26
ATE254133T1 (de) 2003-11-15
JP4021195B2 (ja) 2007-12-12
WO2001040246A1 (en) 2001-06-07
WO2001040243A2 (en) 2001-06-07
CA2389264C (en) 2007-03-06
PT1233973E (pt) 2004-02-27
HUP0500455A2 (hu) 2005-08-29
MXPA01011113A (es) 2002-06-04
TWI249536B (en) 2006-02-21
US20050054605A1 (en) 2005-03-10
ES2208437T3 (es) 2004-06-16
AR029199A1 (es) 2003-06-18
DK1233973T3 (da) 2004-02-16
NO20015373D0 (no) 2001-11-02
IL145903A (en) 2006-04-10
TR200301971T4 (tr) 2004-01-21
EP1233973B1 (en) 2003-11-12
AU761029B2 (en) 2003-05-29
NZ514777A (en) 2004-01-30
HK1047941A1 (zh) 2003-03-14
WO2001040243A3 (en) 2001-12-13
CN1152042C (zh) 2004-06-02
BR0016126A (pt) 2002-08-06
US6605597B1 (en) 2003-08-12
AU7938301A (en) 2002-03-21
DE60006576T2 (de) 2004-09-16
CA2389264A1 (en) 2001-06-07
JP2003516325A (ja) 2003-05-13
DE60006576D1 (de) 2003-12-18

Similar Documents

Publication Publication Date Title
ZA200204380B (en) Partial or full A1 agonists-N6 heterocyclic 5'-thio substituted adenosine derivatives.
MA26831A1 (fr) Derives de benzodiazepine."
ZA200204379B (en) N6 heterocyclic 8-modified adenosine derivatives.
ZA200000894B (en) 4-Phenyl-pyridine derivatives.
ZA200201055B (en) Amino-triazolopyridine derivatives.
HK1034978A1 (en) Adenosine derivatives.
PT1070708E (pt) Derivados de triazol
ZA200109595B (en) 13-methyl-erythromycin derivatives.
AU1937201A (en) N6 heterocyclic 5' modified adenosine derivatives
HK1046411A1 (en) 5-Phenyl-pyrimidine derivatives.
HK1046400A1 (en) Substituted 2-dialkylaminoalkylbiphenyl derivatives
HK1039124A1 (en) Phthalzaine derivatives phosphodiesterase 4 inhibitors.
MXPA00011504A (es) Derivados heterociclicos sustituidos.
ZA200201276B (en) 3-Amino-2-phenyl-propane derivatives.
PT1129079E (pt) Derivados de triazina 2,4-dissubstituidos
ZA200204492B (en) Heterocyclic derivatives.
IL141602A0 (en) Bridged heterocyclic derivatives
MXPA01011285A (es) Derivados de tio-oxindol.
ZA994369B (en) Acridin derivatives.
EP1240156A4 (en) 3-METHYL CHROME OR THIOCHROME DERIVATIVES
NO20015397L (no) 1,5-Benzodiazepin-derivater
ZA9710062B (en) Heterocyclic derivatives.
GB2350361B (en) 3,4,5-tricyanophenyl derivatives
GB9812410D0 (en) Heterocyclic derivatives
GB9809351D0 (en) Heterocyclic derivatives